Affiliation:
1. Division of Mineral Metabolism (C.R.P., D.J.H.), Nottingham NG5 1PB, United Kingdom
2. Departments of Clinical Chemistry (P.J.B.), Nottingham NG5 1PB, United Kingdom
3. Radiology (K.J.F.), City Hospital, Nottingham NG5 1PB, United Kingdom
Abstract
We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism. The treatment group [n = 14; T score ≤ −2.5 sd at the femoral neck (FN) or T ≤ −1.0 sd plus previous nonvertebral fracture] was given alendronate 10 mg/d for 24 months. The second group (n = 18; T score > −2.5 sd at the FN) was untreated. Biochemistry was repeated at 1.5, 3, 6, 12, 18, and 24 months, and dual-energy x-ray absorptiometry at 12 and 24 months.
There were no significant between-group baseline differences in calcium, creatinine, or PTH. Alendronate-treated patients gained bone at all sites [lumbar spine (LS), 1 yr gain, +7.3 ± 1.7%; P < 0.001; 2 yr, +7.3 ± 3.1%; P = 0.04). Untreated patients gained bone at the LS over 2 yr (+4.0 ± 1.8%; P = 0.03) but lost bone elsewhere. Calcium fell nonsignificantly in the alendronate group between baseline (2.84 ± 0.12 mmol/liter) and 6 wk (2.76 ± 0.09 mmol/liter), with a nonsignificant rise in PTH (baseline, 103.5 ± 14.6 ng/liter; 6 wk, 116.7 ± 15.6 ng/liter). By 3 months, values had reverted to baseline.
In primary hyperparathyroidism, alendronate is well tolerated and significantly improves bone mineral density at the LS (with lesser gains at FN and radius), especially within the first year of treatment. Short-term changes in calcium and PTH resolve by 3 months.
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference18 articles.
1. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.;Selby;N Engl J Med,1986
2. The correlation of bone mineral density and biochemical markers to fracture risk;Adachi;Calcif Tissue Int,1996
3. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.;Guo;J Clin Endocrinol Metab,1996
4. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status.;Schmidli;Clin Endocrinol (Oxf),1990
5. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.;Reasner;J Clin Endocrinol Metab,1993
Cited by
112 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献